HK Stock Market Move | YOURAN DAIRY (09858) rose more than 7%, with the impact of biological asset impairment reducing the apparent profit. The turning point is gradually releasing upward elasticity.
You Ran Agriculture (09858) rose more than 7%, as of the time of publication, it increased by 7.04%, to 4.26 Hong Kong dollars, with a turnover of 182 million Hong Kong dollars.
YOURAN DAIRY (09858) surged more than 7%, closing at a 7.04% increase to HKD 4.26 with a trading volume of 182 million Hong Kong dollars.
In terms of news, YOURAN DAIRY's 2025 annual performance showed that the company achieved operating income of 25.674 billion RMB, a year-on-year increase of 4.51%. The net loss was 432 million RMB, a year-on-year decrease of 37.42%. Guotai Haitong pointed out that the company's net profit attributable to shareholders in 2025 was -432 million RMB, mainly affected by a 3.91 billion RMB year-on-year increase in impairment loss of biological assets to 4.312 billion RMB, primarily due to the increase in culling cows and the decrease in mother cow valuation; subsidy expenses decreased by 29.2% year-on-year to 2.29 billion RMB. The price of raw milk continued to stabilize, benefiting from the shortage of reserve cows in the supply side and weakening impact from imports, as well as the continuous release of deep processing capacity on the demand side, indicating a strong upward trend in milk prices in 2026. With the reversal of the meat and milk cycle, the company's profit elasticity is expected to gradually increase.
Related Articles

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.

There is currently disagreement within OpenAI about when to IPO: Altman hopes for the fourth quarter, but the CFO believes they are not yet ready.
Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.

There is currently disagreement within OpenAI about when to IPO: Altman hopes for the fourth quarter, but the CFO believes they are not yet ready.

RECOMMEND

Hong Kong Stocks Surge! Buying Opportunity Or Wait And See? Analysts Provide Comprehensive Interpretation
02/04/2026

Narrative Drives Everything As China’s AI Newcomers Enter An Era Of Extreme Volatility, Retail Investors Flood In
02/04/2026

Fund Cohort Stocks Rally As Institutional Confidence In Hong Kong Equities Shows Signs Of Repair
02/04/2026


